- Fund Type: Open-End Fund
- Objective: International Equity
- Asset Class: Equity
- Geographic Focus: International
Snapshot for AcomeA America (ACAMRA2)
| Year To Date: | +19.07% | 3-Month: | +9.77% | 3-Year: | - | 52-Week Range: | 12.16 - 15.60 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +7.16% | 1-Year: | +23.41% | 5-Year: | - | Beta vs FTS9AMCS: | 0.89 |
Fund Profile & Information for ACAMRA2
AcomeA America is an open-end fund incorporated in Italy. The Fund's objective is to provide long-term growth. The Fund invests primarily in stocks that are issued in the Americas and denominated in US dollars. The Fund may have residual investments in emerging countries.
| Inception Date: | 06-01-2011 | Telephone: | 39-02-9768-5025 |
|---|---|---|---|
| Managers: | MATTEO DIRUPATI | ||
| Web Site: | www.acomea.it | ||
Fundamentals for ACAMRA2
| NAV | (on 2013-05-16) 15.52 |
|---|---|
| Assets (M) | (on 2013-05-16) 19.38 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for ACAMRA2
No dividends reported
Fees & Expenses for ACAMRA2
| Front Load | - |
|---|---|
| Back Load | 4.00 |
| Current Mgmt Fee | 0.90 |
| Redemption Fee | 4.00 |
| 12b1 Fee | - |
| Expense Ratio | 2.10 |
Top Fund Holdings for ACAMRA2
Filing Date: 02/28/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| AcomeA Liquidit | 100,000 | 869,900 | 4.628% |
| Marvell Technology Group Ltd | 55,000 | 424,905 | 2.260% |
| St Jude Medical Inc | 12,500 | 392,014 | 2.085% |
| Fusion-io Inc | 30,000 | 387,348 | 2.061% |
| Hewlett-Packard Co | 24,000 | 369,725 | 1.967% |
| General Electric Co | 20,000 | 355,222 | 1.890% |
| Microsoft Corp | 16,500 | 350,862 | 1.866% |
| Merck & Co Inc | 10,000 | 326,844 | 1.739% |
| Intel Corp | 20,000 | 318,966 | 1.697% |
| Kohl's Corp | 9,000 | 317,360 | 1.688% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page